Yes, Daxxify is FDA approved. The product received clearance on September 27, 2023, as a neuromodulator indicated for the temporary improvement of moderate to severe glabellar lines (frown lines between the eyebrows) in adults. It is manufactured by Revance Therapeutics and represents the first new botulinum toxin Type A product approved by the FDA in nearly two decades.
Injectables
Is Daxxify FDA Approved? Status, Indications, and How It Compares to Botox
Daxxify received FDA approval in September 2023 as a long-acting neuromodulator with a different formulation and duration profile than Botox.
Daxxify's 6-month duration extends treatment intervals versus Botox's standard 12-week schedule, but it's currently approved only for glabellar lines.
Daxxify's FDA approval came via a Biologics License Application (BLA), not a 510(k) clearance. This pathway required full clinical trial data demonstrating safety and efficacy. The product is currently approved only for glabellar lines; it is not yet approved for crow's feet, forehead lines, or other off-label uses that practitioners routinely pursue with Botox and Dysport. Any use beyond the glabellar indication remains off-label, subject to standard state scope-of-practice rules.
How Daxxify Differs from Botox
The critical distinction between Daxxify and Botox (onabotulinumtoxinA, Allergan/AbbVie) lies in formulation and duration. Daxxify uses a proprietary peptide-excipient technology (the "Revance Immobility Technology") that stabilizes the toxin without human serum albumin or gelatin. This formulation allows for a longer duration of effect: clinical trials showed results lasting approximately 6 months, compared to Botox's typical 3–4 month window. Some patients in Daxxify trials maintained visible improvement for up to 6 months; repeat dosing intervals can stretch to 6 months versus the standard 12-week Botox schedule.
Daxxify also differs in onset. The product reaches peak effect around 2 weeks, similar to Botox, but some data suggest a slightly faster plateau in certain patients.
Practical Considerations for Practice Owners
From a practice economics standpoint, Daxxify's longer duration is a double-edged sword. Extended intervals between treatments reduce patient visit frequency but may increase per-unit pricing and rebate structures. Revance offers the Evolus Rewards program (formerly the Revance loyalty program), which provides rebates and volume incentives comparable to AbbVie's Alle program and Galderma's Aspire platform. Verify current pricing and rebate terms with your Revance representative, as these shift seasonally.
Daxxify's limited approval to glabellar lines also means it cannot yet replace Botox as a one-product solution for a full-face neuromodulator program. Many practices will continue to stock Botox for crow's feet and forehead lines while introducing Daxxify as an alternative for glabellar treatment or as a patient retention tool for those seeking longer intervals between appointments.
Off-Label Use and Regulatory Nuance
Practitioners may use Daxxify off-label for crow's feet, forehead lines, and other dynamic wrinkles under the same legal framework that permits off-label use of any FDA-approved drug or biologic—provided the prescriber has a sound medical rationale and the patient is informed. However, marketing or advertising off-label indications remains prohibited. State medical boards and the FDA monitor off-label promotion closely.
Daxxify's approval does not change the Corporate Practice of Medicine doctrine or supervision requirements in states that restrict non-physician injection of neuromodulators. Verify your state's delegation and supervision rules with your state medical board; approval of a new product does not expand scope of practice.
Availability and Supply
Daxxify became commercially available in late 2023 and early 2024. Supply has ramped steadily, though some practices report periodic allocation constraints during peak demand periods. Confirm current availability and lead times with your Revance sales representative.
Frequently asked questions
When did Daxxify get FDA approved?
Daxxify received FDA approval on September 27, 2023. It was approved via a Biologics License Application (BLA) pathway, making it the first new botulinum toxin Type A product approved by the FDA in nearly two decades.
How long does Daxxify last compared to Botox?
Daxxify lasts approximately 6 months, compared to Botox's typical 3–4 month duration. Some patients in clinical trials maintained visible improvement for up to 6 months, allowing repeat dosing intervals to stretch to 6 months versus Botox's standard 12-week schedule.
What areas is Daxxify FDA approved for?
Daxxify is currently approved only for glabellar lines (frown lines between the eyebrows) in adults. It is not yet approved for crow's feet, forehead lines, or other areas; any use beyond glabellar lines remains off-label.
Can I use Daxxify off-label for forehead lines and crow's feet?
Yes, practitioners may use Daxxify off-label for crow's feet, forehead lines, and other dynamic wrinkles under the same legal framework as any FDA-approved biologic, provided you have sound medical rationale and inform the patient. However, marketing or advertising off-label indications is prohibited.
What is different about Daxxify's formulation?
Daxxify uses proprietary peptide-excipient technology (Revance Immobility Technology) that stabilizes the toxin without human serum albumin or gelatin. This formulation enables the longer 6-month duration and may allow slightly faster peak effect in certain patients compared to Botox.
Does Daxxify approval change scope of practice rules for injectors?
No. Daxxify's approval does not expand scope of practice or change supervision requirements in states that restrict non-physician injection of neuromodulators. Verify your state's delegation and supervision rules with your state medical board.
Free weekly brief
Get the free weekly brief.
The week's most important moves in medical aesthetics — distilled to a two-minute read, free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief every morning. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.